Gros Francois-Xavier

Oncologie hémato.

Hôpital Haut-lévêque
Pessac, France

113 Activités

437 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Lymphomes Lymphome B Lymphome B diffus à grandes cellules Leucémies Lymphome malin non hodgkinien Syndrome de libération de cytokines Leucémie-lymphome lymphoblastique à précurseurs B et T Tumeurs hématologiques Maladie de Hodgkin

Collaborateurs

Houot Roch

Hôpital Pontchaillou, Rennes, France

Cartron Guillaume

Hôpital Saint-Éloi, Montpellier, France

Morschhauser Franck

Centre Hospitalier de Lille, Lille, France

Gastinne Thomas

Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Gilead

31 collaboration(s)

Dernière en 2023

Novartis

11 collaboration(s)

Dernière en 2022

A+A

8 collaboration(s)

Dernière en 2023

B3TSI

7 collaboration(s)

Dernière en 2023

Dernières activités

MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma

Essai Clinique (The Lymphoma Academic Research Organisation) 13 mars 2024

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse: Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Essai Clinique (The Lymphoma Academic Research Organisation) 14 février 2024

HEMATOVAC: Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte

Essai Clinique (CHU Poitiers) 09 février 2024

DALY 2-EU: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT

Essai Clinique (Miltenyi Biomedicine GmbH) 31 janvier 2024

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.